A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.

A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Abstract Text:

Sheri K Dennison,Samuel A Jacobs,John W Wilson,Janell Seeger,Terrence P Cescon,Jane M Raymond,Charles E Geyer,Norman Wolmark,Sandra M Swain,

This was a phase II multi-institutional trial to determine the efficacy and tolerability of gefitinib (Iressatrade) and docetaxel as first-line treatment in patients with metastatic breast cancer. All patients had histologically confirmed breast cancer with metastatic disease. They were permitted to have received adjuvant chemotherapy, but no prior docetaxel or prior chemotherapy for metastatic disease. Patients received gefitinib 250 mg once daily and docetaxel 75 mg/m(2) every 3 weeks, until tumor progression, toxicity or other reasons for discontinuation. Thirty-three patients were enrolled and received a median of 5 cycles of treatment. The clinical benefit rate was 51.5% (95% CI: 33.5-69.2%). There were 1 confirmed complete response and 12 confirmed partial responses, and the overall objective response rate was 39.4% (95% CI: 22.9-57.9%). Four patients had stable disease for > or =24 weeks. The median duration of clinical benefit was 10.9 months (95% CI: 6.0-17.6 months). The most common reason for study discontinuation was disease progression (16 patients), followed by toxicity (ten patients). Toxicities were mainly attributable to docetaxel, including > or =grade 3 neutropenia in 43% of patients. The combination of gefitinib and docetaxel is an active regimen in patients with previously untreated metastatic breast cancer, with a clinical benefit rate and toxicity profile in the range of that reported for docetaxel alone.

A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Publishing Authors By Initials

SK Dennison,SA Jacobs,JW Wilson,J Seeger,TP Cescon,JM Raymond,CE Geyer,N Wolmark,SM Swain,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Investigational new drugs

VOLUME: 25

Page Numbers: 545-51

Journal Abbreviation:

ISSN: 0167-6997

DAY: 12

MONTH: 06

YEAR: 2007

A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309330

A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.

AFFILIATION: Walter Reed Army Medical Center, 6900 Georgia Ave. NW, Washington, DC 20307, USA. dennisonsk@mail.nih.gov

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Invest New Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A phase II clinical trial of ZD1839 Iressa in combination with docetaxel as first-line treatment in patients with advanced breast cancer Related Publications

• A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
• A synthesis of dl-dethiobiotin and some related compounds.
• Characterisation of enamel white spot lesions using X-ray micro-tomography.
• Characterization of nanoindentation-induced residual stresses in human enamel by Raman microspectroscopy.
• Comparative assessment of hardening of demineralized dentin under lining materials using an ultramicroindentation system.
• Determination of endogenous norepinephrine levels in different chambers of the rat heart by capillary electrophoresis coupled with amperometric detection.
• Diamond microelectrodes for in vitro electroanalytical measurements: current status and remaining challenges.
• Differences in sympathetic neuroeffector transmission to rat mesenteric arteries and veins as probed by in vitro continuous amperometry and video imaging.
• Effect of Training Volume on HDL-Cholesterol: A 6-year Case Study: 949: June 2 10:15 AM - 10:30 AM.
• Environmental and intrinsic factors lead to antigen unresponsiveness in CD4(+) recent thymic emigrants from aged mice.
• Facile: a command-line network compiler for systems biology.
• Functional significance of strain distribution in the human mandible under masticatory load: numerical predictions.
• High mucosal serotonin availability in neonatal guinea pig ileum is associated with low serotonin transporter expression.
• In vitro continuous amperometric monitoring of 5-hydroxytryptamine release from enterochromaffin cells of the guinea pig ileum.
• In vitro continuous amperometry with a diamond microelectrode coupled with video microscopy for simultaneously monitoring endogenous norepinephrine and its effect on the contractile response of a rat mesenteric artery.
• Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
• Influenza in Scotland in the early months of 1949.
• Kinetics of hydrolysis and displacement reactions of beta, beta1-dichlorodiethyl sulfide and of beta-chloro-beta1-hydroxydiethyl sulfide.
• On the design of dental resin-based composites: A micromechanical approach.
• Open access and medicinal chemistry.
• Optically transparent diamond electrode for use in ir transmission spectroelectrochemical measurements.
• Persistent depots of influenza antigen fail to induce a cytotoxic CD8 T cell response.
• Personal-protection measures against mosquitoes: a study of practices and costs in a district, in the Indian state of Orissa, where malaria and lymphatic filariasis are co-endemic.
• Rapid default transition of CD4 T cell effectors to functional memory cells.
• Restoration of non-carious cervical lesions Part II. Restorative material selection to minimise fracture.
• SAP is required for Th cell function and for immunity to influenza.
• Simultaneous surveys of food consumption in various camps in the United States Army.
• The laboratory investigation of virus diseases.
• Ultrastructure of dentine carious lesions.
• Unique ability of activated CD4+ T cells but not rested effectors to migrate to non-lymphoid sites in the absence of inflammation.